Drug Profile
Exeporfinium chloride - Destiny Pharma
Alternative Names: XF 73Latest Information Update: 22 Nov 2022
Price :
$50
*
At a glance
- Originator Destiny Pharma
- Developer China Medical System; Destiny Pharma; National Institute of Allergy and Infectious Diseases
- Class Amines; Anti-inflammatories; Antibacterials; Benzene derivatives; Chlorinated hydrocarbons; Ethers; Porphyrins; Small molecules
- Mechanism of Action Cell membrane permeability modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Staphylococcal infections
- Preclinical Bacterial infections; Gram-negative infections; Gram-positive infections; Mucositis; Skin and soft tissue infections
Most Recent Events
- 15 Nov 2022 Preclinical trials in Bacterial infections (Prevention) in United Kingdom (Topical)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Staphylococcal-infections in United Kingdom (Topical)
- 05 Jul 2022 Preclinical trials in Mucositis (Prevention) in USA (PO) (9379327; Destiny Pharmaceutical pipeline, July 2022)